In its first major partnership, Predix Pharmaceuticals Holdings Inc. could receive more than $307.5 million per terms of a new deal with Amgen Inc. on S1P1 modulators for autoimmune diseases. (BioWorld Today)

In its first major partnership, Predix Pharmaceuticals Holdings Inc. could receive more than $307.5 million per terms of a new deal with Amgen Inc. on S1P1 modulators for autoimmune diseases. (BioWorld Today)

In a disappointing case of déj vu, investors drove down shares in Genitope Corp. by 48.6 percent after learning that a Phase III study of its lead cancer treatment would last longer than expected. (BioWorld Today)

In a disappointing case of déj vu, investors drove down shares in Genitope Corp. by 48.6 percent after learning that a Phase III study of its lead cancer treatment would last longer than expected. (BioWorld Today)